ALKS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALKS is a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 available. The stock has constructive technical momentum, positive analyst revisions, strong year-over-year revenue growth, and no negative insider or congress-trading pressure. While earnings were weak this quarter, the company’s growth in revenue and favorable Wall Street outlook support a buy decision at current levels for someone who wants to enter now rather than wait.
ALKS shows a bullish short-to-long trend structure: SMA_5 is above SMA_20, and SMA_20 is above SMA_200, which is a positive alignment. MACD histogram is positive and expanding, confirming upward momentum. RSI_6 at 63.33 suggests the stock is not overbought yet and still has room to run. Price at 35.35 is slightly below the first resistance at 36.02 and above the pivot at 34.58, so the stock is holding a constructive trend near resistance rather than breaking down.
["Needham raised its price target to $50 and kept a Buy rating after Q1 results.", "UBS raised its target to $48 and kept a Buy rating, citing growing interest in the orexin pipeline and long-term optionality.", "Q1 revenue rose 28.19% year over year to $392.9M, showing strong top-line growth.", "Revenue estimates have seen more upward than downward revisions over the last three months.", "The stock is supported by bullish moving averages and positive MACD momentum.", "No significant negative hedge fund, insider, or congress-trading trends were reported."]
["Q1 net income was negative at -$66.48M and EPS declined sharply year over year.", "Gross margin slipped year over year to 81.36%, showing some pressure on profitability quality.", "Open interest put-call ratio is above 1.0, indicating some defensive positioning remains in the options market.", "The stock is trading near resistance at 36.02, so near-term upside may be incremental rather than explosive."]
In Q1 2026, Alkermes posted revenue of $392.9M, up 28.19% year over year, which is a strong growth signal. However, net income fell to -$66.48M and EPS dropped to -0.40, showing that earnings profitability weakened sharply this quarter. Gross margin also declined to 81.36%. For a long-term investor, the main takeaway is that top-line growth is healthy, but profitability remains uneven.
Analyst sentiment has turned clearly positive recently. Needham and UBS both raised price targets and maintained Buy ratings, lifting targets to $50 and $48, respectively. Wolfe Research initiated with Outperform and $45. Earlier in the period, BofA was neutral with a lower target near $34-$36, but the more recent revisions are more bullish. Overall Wall Street view is constructive, with the pro side emphasizing ALKS’s profitable base business, sleep franchise expansion, and orexin pipeline optionality, while the cautious side focuses on valuation, earnings volatility, and execution risk in the pipeline.
